Second surgical treatment of retroperitoneal persistent disease in epithelial ovarian cancer.
OBJECTIVE
This report retrospectively analyzes 9 cases of epithelial ovarian cancer with persistent retroperitoneal metastasis after intraperitoneal surgery (without systematic lymphadenectomy) and chemotherapy.


METHODS
All 9 patients were diagnosed as FIGO stage I to IV at the time of primary surgery. They received combined postoperative chemotherapy (8 cases with a cisplatin-based regimen and 1 with adriamycin and endoxan). They were submitted to pelvic and paraaortic lymphadenectomy at the National Cancer Institute of Milan during the period 1990-1994.


RESULTS
All patients presented no evidence of disease in the abdominal cavity but retroperitoneal metastasis, which was the unique metastatic site. Chemotherapy was administered as adjuvant therapy after lymphadenectomy. Six patients were free of disease for 14 to 61 months. One patient with vaginal recurrence at the 18th month was treated with radiotherapy and chemotherapy, but died of widespread disease 25 months after lymphadenectomy. Two patients with massive positive lymph nodes dies of brain and lung metastasis 20 and 6 months later, respectively.


CONCLUSIONS
We conclude that retroperitoneal metastasis may be the only site of persistent disease and that systematic lymphadenectomy technically feasible in this situation to increase the opportunity for local disease control and to obtain a good result.
Lupi
G
G
Surgical Gynecologic Oncology, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan, Italy.
Fontanelli
R
R
Jin
R
R
Grosso
G
G
D000328:Adult; D018394:CA-125 Antigen / Q000032:analysis; D003131:Combined Modality Therapy; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008197:Lymph Node Excision; D008875:Middle Aged; D010051:Ovarian Neoplasms / Q000473:pathology / Q000601:surgery*; D012186:Retroperitoneal Neoplasms / Q000473:pathology / Q000556:secondary / Q000601:surgery*; D012189:Retrospective Studies
D018394:CA-125 Antigen